| Inclusion Criteria: | Pts with detectable disease limited to bladder, no clinical or radiographically evaluable disease needed, For metastatic disease, at least 1 site must be measurable.
No previous therapy for metastatic disease allowed. Relapsed pts, (neo)adjuvant therapy is OK. Prior intravessical therapy is ok.
Previously treated pts myst fit guidelines: prior cummulative dose of doxorubicin</=200mg/m2; no more than 15% of bone marrow in previous areas of irradiation; no delays of >1 wk in delivering any previous chemo regimen.
Zubrod</=2(3 if of recent onset & due to cancer);normal WBC,ANC>/=1800;platelets>150,000;transaminase</=2xULN.
Conjugataed bilirubin</=1.0mg/dL(or total bilirubin<2mg/dL); creatinine>/=45mL/min; CL(cr)=[(140-age) x wt(kg)]/{72 x Creat(mg/dL)] For females, x 0.85).
Pts with uncontrolled CNS metastases are not eligible.
Pts with an abnormal EKG or a history of cardiac disease, or prior exposure to doxorubicin must have a determination of LV function.
Women of child-bearing potential must have a neg preg. test before starting therapy.
.Histologic proof of urothelial small cell carcinoma, for mixed histology, small cell must be the clinically relevant component. Dr. Siefker-Radtke will serve as the final arbiter regarding discussion on mixed histology. |